ArticleNature genetics2023
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity.
Abstract read
In one paragraph
Article in Nature genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Article
- Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence.International journal of molecular sciences · 2026Review
- Protocol for Mesothelioma Observational study of Risk prediction and Generation of paired benign-meso tissue samples, Including a Nested MRI Substudy (Meso-ORIGINS).BMJ open respiratory research · 2026Article
- BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma.Thoracic cancer · 2026Article
- Genomic landscape of pleural mesothelioma in Japanese patients: A comprehensive analysis using nationwide database.Translational oncology · 2026Article
- Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.Nature genetics · 2026Article
- Genetic and Immunohistochemical Profiling of Malignant Mesothelioma With Brain Metastasis: A Report of Two Cases.Cancer reports (Hoboken, N.J.) · 2026Article
- Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Tumour promotion through the lens of evolution.Nature · 2026Review
- Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies.Molecular oncology · 2026Article
- Multi-omics integration reveals tumor and microenvironmental heterogeneity in malignant pleural mesothelioma.Discover oncology · 2026Article
- Interpretable Cancer Survival Prediction by Fusing Semantic Labelling of Cell Types and Whole Slide Images.Interdisciplinary sciences, computational life sciences · 2026Article
- A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts.Clinical and experimental medicine · 2026Article
- A signature-agnostic test for differences between tumor mutation spectra reveals carcinogen and ancestry effects.Communications biology · 2026Article
- Construction and validation of a prognostic risk score model for malignant mesothelioma.Discover oncology · 2026Article
- Integrative multi-omic analyses identify major axes of heterogeneity in chronic obstructive pulmonary disease and uncover their molecular contributors.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy.Frontiers in oncology · 2026Review
- Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors.
Lise Mangiante *Rare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.ORCID http://orcid.org/0000-0001-8309-0950
Nicolas Alcala *Rare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.ORCID http://orcid.org/0000-0002-5961-5064
Alexandra Sexton-Oates *Rare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Alex Di Genova *Rare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Abel Gonzalez-PerezInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8582-4660
Azhar KhandekarDepartment of Cellular and Molecular Medicine, Department of Bioengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Erik N BergstromDepartment of Cellular and Molecular Medicine, Department of Bioengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Jaehee KimInstitute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5210-2004
Xiran LiuInstitute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA.
Ricardo Blazquez-EncinasMaimonides Biomedical Research Institute of Cordoba, Córdoba, Spain.
Colin GiacobiRare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Nolwenn Le StangUMR INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, MESOPATH-MESOBANK, Department of Biopathology, Cancer Centre Léon Bérard, Lyon, France.
Sandrine BoyaultCancer Genomic Platform, Translational Research and Innovation Department, Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0002-2297-6894
Cyrille CueninEpiGenomics and Mechanisms Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Severine Tabone-EglingerUMR INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, MESOPATH-MESOBANK, Department of Biopathology, Cancer Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0003-4247-1321
Francesca DamiolaUMR INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, MESOPATH-MESOBANK, Department of Biopathology, Cancer Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0002-0238-1252
Catherine VoegeleRare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Maude ArdinTumor Escape, Resistance and Immunity Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.
Marie-Cecile MichalletTumor Escape, Resistance and Immunity Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.
Lorraine SoudadeRare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Tiffany M DelhommeRare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.ORCID http://orcid.org/0000-0003-0265-4246
Arnaud PoretRare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Marie BrevetCypath and Cypath-rb, Villeurbanne, France.
Marie-Christine CopinUniversity of Lille, Centre Hospitalier Universitaire Lille, Institut de Pathologie, Tumorothèque du Centre de Référence Régional en Cancérologie, Lille, France.
Sophie Giusiano-CourcambeckDepartment of Pathology, Centre Hospitalier Universitaire Nord, Marseille, France.
Diane DamotteCentre de Recherche des Cordeliers, Inflammation, Complement and Cancer Team, Sorbonne Université, INSERM, Université de Paris, Paris, France.
Cecile GirardTumorothèque Centre Hospitalier Universitaire de Nantes, Nantes, France.
Veronique HofmanUniversité Côte d'Azur, Laboratory of Clinical and Experimental Pathology, Nice Center Hospital, FHU OncoAge, Biobank BB-0033-00025 and IRCAN Inserm U1081/CNRS 7284, Nice, France.
Paul HofmanUniversité Côte d'Azur, Laboratory of Clinical and Experimental Pathology, Nice Center Hospital, FHU OncoAge, Biobank BB-0033-00025 and IRCAN Inserm U1081/CNRS 7284, Nice, France.
Jérôme MourouxUniversité Côte d'Azur, Department of Thoracic Surgery, Nice Center Hospital, FHU OncoAge and IRCAN Inserm U1081/CNRS 7284, Nice, France.
Charlotte CohenDepartment of Thoracic Surgery, FHU OncoAge, Nice Pasteur Hospital, Université Côte d'Azur, Nice, France.
Stephanie LacommeNancy Regional University Hospital, Centre Hospitalier Régional Universitaire, CRB BB-0033-00035, INSERM U1256, Nancy, France.
Julien MazieresToulouse University Hospital, Université Paul Sabatier, Toulouse, France.
Vincent Thomas de MontprevilleDepartment of Pathology, Marie Lannelongue Hospital, Le Plessis Robinson, France.
Corinne PerrinHospices Civils de Lyon, Institut de Pathologie, Centre de Ressources Biologiques des HCL, Tissu-Tumorothèque Est, Lyon, France.
Gaetane PlanchardCentre Hospitalier Universitaire de Caen, MESOPATH Regional Center, Caen, France.
Nathalie RousseauCentre Hospitalier Universitaire de Caen, MESOPATH Regional Center, Caen, France.
Isabelle RouquetteCentre de Pathologie des Côteaux, Centre de Ressources Biologiques (CRB Cancer), IUCT Oncopole, Toulouse, France.
Christine SaganTumorothèque Centre Hospitalier Universitaire de Nantes, Nantes, France.
Arnaud ScherpereelUniversity of Lille, Centre Hospitalier Universitaire Lille, INSERM, OncoThAI, NETMESO Network, Lille, France.
Francoise ThivoletHospices Civils de Lyon, Institut de Pathologie, Centre de Ressources Biologiques des HCL, Tissu-Tumorothèque Est, Lyon, France.
Jean-Michel VignaudDepartment of Biopathology, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-les-Nancy, France.
Didier JeanCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Functional Genomics of Solid Tumors, Paris, France.
Anabelle Gilg Soit IlgDirection Santé Environnement Travail, Santé Publique France, Paris, France.
Robert OlasoUniversité Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France.ORCID http://orcid.org/0000-0001-7631-9657
Vincent MeyerUniversité Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France.
Anne Boland-AugeUniversité Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France.ORCID http://orcid.org/0000-0001-8789-5676
Jean-Francois DeleuzeUniversité Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France.ORCID http://orcid.org/0000-0002-5358-4463
Janine AltmullerCologne Centre for Genomics, Cologne, Germany.
Peter NuernbergCologne Centre for Genomics, Cologne, Germany.
Alejandro Ibáñez-CostaMaimonides Biomedical Research Institute of Cordoba, Córdoba, Spain.ORCID http://orcid.org/0000-0003-4649-0095
Justo P CastañoMaimonides Biomedical Research Institute of Cordoba, Córdoba, Spain.ORCID http://orcid.org/0000-0002-3145-7287
Sylvie LantuejoulUMR INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, MESOPATH-MESOBANK, Department of Biopathology, Cancer Centre Léon Bérard, Lyon, France.
Akram GhantousEpiGenomics and Mechanisms Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France.
Charles MaussionOwkin, New York, NY, USA.ORCID http://orcid.org/0000-0003-2266-5276
Pierre CourtiolOwkin, New York, NY, USA.
Hector Hernandez-VargasUMR INSERM 1052, CNRS 5286, UCBL1, Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0001-6045-2103
Christophe CauxTumor Escape, Resistance and Immunity Department, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Lyon, France.
Nicolas GirardInstitut Curie, Institut du Thorax Curie Montsouris, Paris, France.
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4925-8988
Ludmil B AlexandrovDepartment of Cellular and Molecular Medicine, Department of Bioengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
Françoise Galateau-SalleUMR INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, MESOPATH-MESOBANK, Department of Biopathology, Cancer Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0002-2814-1644
Matthieu FollRare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France. follm@iarc.who.int.ORCID http://orcid.org/0000-0001-9006-8436
Lynnette Fernandez-CuestaRare Cancers Genomics Team, Genomic Epidemiology Branch, International Agency for Research on Cancer/World Health Organization, Lyon, France. fernandezcuestal@iarc.who.int.ORCID http://orcid.org/0000-0002-0724-6703
Funding
World Health Organization 001
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using multiomics factor analysis, we demonstrate that the current World Health Organization classification only accounts for up to 10% of interpatient molecular differences. Instead, the MESOMICS project paves the way for a morphomolecular classification of MPM based on four dimensions: ploidy, tumor cell morphology, adaptive immune response and CpG island methylator profile. We show that these four dimensions are complementary, capture major interpatient molecular differences and are delimited by extreme phenotypes that-in the case of the interdependent tumor cell morphology and adapted immune response-reflect tumor specialization. These findings unearth the interplay between MPM functional biology and its genomic history, and provide insights into the variations observed in the clinical behavior of patients with MPM.
Indexed as
Lung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsBiomarkers, TumorHumansMultiomicsBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.